0001493152-23-005880.txt : 20230223 0001493152-23-005880.hdr.sgml : 20230223 20230223163042 ACCESSION NUMBER: 0001493152-23-005880 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230222 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230223 DATE AS OF CHANGE: 20230223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 23660154 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 or 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 22, 2023

Rennova Health, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-35141		68-0370244
(Commission File Number)		(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida		33401
(Address of Principal Executive Offices)		(Zip Code)

(561) 855-1626

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered under Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure

On February 22, 2023, Rennova Health, Inc. (the “Company”) issued a press release announcing that Seamus Lagan, our Chief Executive Officer, would be interviewed on Uptick Newswire’s “Stock Day” podcast with Everett Jolly. A copy of the press release is attached hereto as Exhibit 99.1 and a transcript of the interview is attached hereto as Exhibit 99.2.

The information furnished pursuant to this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits

(d)

Exhibits

Exhibit No.		Exhibit Description

99.1		Press Release dated February 22, 2023

99.2		Transcript of Interview of Seamus Lagan

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 23, 2023	RENNOVA HEALTH, INC.

	By:	/s/ Seamus Lagan
		Seamus Lagan
		Chief Executive Officer
		(principal executive officer)

3

EX-99.1 2 ex99-1.htm

Exhibit 99.1

RENNOVA HEALTH, INC. PROVIDES UPDATE ON 2022 FINANCIALS AND MYRTLE RECOVERY CENTERS

WEST PALM BEACH, Fla. (Feb 22, 2023) – Rennova Health, Inc. (OTC: RNVA) Chief Executive Officer Seamus Lagan recently joined Stock Day host Everett Jolly to provide an update on 2022 financial statements and other activities.

Jolly began the interview by referring to the improved previous quarterly reports and asked if the Company could provide an update on the 2022 financial statements that are soon due for filing. Lagan responded by confirming that filings would be made on time and would show a continued improvement in revenues and profitability for the 4th quarter and a significant improvement from previous years.

Jolly asked for an update on the behavioral health division. Lagan confirmed that in anticipation of opening, a new web site describing the services has been launched at www.myrtlerecoverycenters.com He confirmed that relevant license applications for medically supervised withdrawal, residential recovery and OBOT services had been submitted and were expected in the near future. He also confirmed that building and decorating works including furnishing will be completed in the coming weeks with the facility expected to be ready for patients at the end of March. Opening is predicted to be in the 2^nd quarter of 2023 subject to staffing and licensure.

Jolly then asked if the company had plans to reopen its closed facility or plans to look for additional acquisitions. Lagan stated that the priority was to ensure continued consistency with the current operations and to get the behavioral health facility opened in the second quarter as planned but then explained that consideration would be given to adding behavioral health services at the Jamestown facility and reopening a hospital operation similar in size to the current Big South Fork operations. Lagan also confirmed that the Company was very open to an acquisition strategy to expedite growth.

Jolly ended the interview by asking Lagan what message he would like the Company’s shareholders to take away from the interview. Lagan responded by saying that despite certain hurdles and challenges remaining he believed the Company could continue with its current rate of improvement and create opportunity for shareholders and investors.

To hear Seamus Lagan’s entire interview, follow the link to the podcast here:

Stock Day Media / Rennova Health (RNVA) is Featured on The Stock Day Podcast (audioboom.com)

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About Rennova Health, Inc.

Rennova Health, Inc. (“Rennova,” the “Company,” “we”, “us”, “its” or “our”) is a provider of health care services. The Company owns one operating hospital in Oneida, Tennessee known as Big South Fork Medical Center, a hospital located in Jamestown, Tennessee that it plans to reopen, a physician’s practice in Jamestown, Tennessee that it plans to reopen and a rural clinic in Kentucky. For more information, please visit www.rennovahealth.com

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:

Rennova Health

561-855-1626

info@rennovahealth.com

EX-99.2 3 ex99-2.htm

Exhibit 99.2

Rennova Health, Inc. (RNVA) Interview

CEO Seamus Lagan on Uptick Newswire – February 2023

Speakers: Everett Jolly and Seamus Lagan

Jolly: On today’s show I’m bringing back a returning guest - the last time he was on my show was back in December of last year. I’m talking about no other than Rennova Health, Inc., they trade on the Pink Sheets under the ticker symbol ‘RNVA’. With us today is the CEO, who is going to bring us up-to-speed, Mr. Seamus Lagan. Seamus, welcome back to the show.

Lagan: Everett, thank you for having me back.

Jolly: You know, the last time you were on the show we talked about the last couple of quarters showing the improvement that you had and that you predicted for the year, and it came to fruition. That being said, what are your thoughts on the 2022 audited financial statements, and I know they will be out soon here, they are due. Could you give us an idea of what they’re going to tell us?

Lagan: Everett, we are looking forward to getting the full year financial statements out. They will be out on time and they will confirm a continued increase in services provided and further improved revenues and profitability for the fourth quarter. As you said, in keeping with our message throughout last year. They are going to show a very significant improvement across the board from previous years. Hospital operations continue to be profitable on a monthly basis and we have continued to clean up a lot of old debts and litigation items on our balance sheet. We have been consistent on our message in the past year and firmly believe these financial statements will confirm those achievements.

Jolly: The last time you were on the show we talked about Myrtle Recovery Centers. Where are we with that new behavioral health division? When do you anticipate opening, one, and, two, what is your strategy for the division for the next three to four quarters?

Lagan: That division is progressing really well and in the anticipation of opening we have recently launched the website at MyrtleRecoveryCenters.com Relevant license applications have been submitted to facilitate the division of medically supervised withdrawal, residential recovery, and OBOT services. We expect to have these licenses granted to us fairly quickly. All building and decorating works, including furnishings, will be complete within the next few weeks, meaning the facility will be ready to receive patients by the end of March. The hiring process is already underway for multiple positions and if everything goes to plan here, Everett, and currently there is no reason why it won’t, we should have this first facility open and operating in the second quarter here.

Jolly: What else do you have going on with some of the other hospitals? I know that one is doing really well. I was thinking of the second hospital that you’re getting ready, hopefully, to open again? What are your thoughts on that and where are we at in that process?

Lagan: We continue to consider our best options for the closed Jamestown facility. Our immediate priority is to ensure we have continued consistency with our current operations and make every effort to open this first behavioral health facility in the second quarter as we’ve planned. We will then look at the closed facility and hopefully initiate plans to utilize part of the property as a second behavioral health facility and consider reopening a hospital operation similar in size to our Big South Fork location as a starting point. We certainly hope there will be some acquisition opportunity before the year is out, Everett. We are very open to an acquisition strategy to expedite growth again.

Jolly: You know what really blows my mind about your company is that your market cap is under $3 million, your run rate I think is going to be more than that for Rennova with the first hospital. Do you have any thoughts on that?

Lagan: That is a hard one. Public markets are what they are. We have hurdles out there and challenges that we still have to overcome. Our shareholders have waited a long time to see this recovery Everett, but I firmly believe we can maintain the current rate of improvement and create some renewed opportunity for our shareholders and investors throughout this coming year. We are looking forward to that.

Jolly: You have been listening to Seamus Lagan. He is the CEO of Rennova Health. This is my thought, and I am entitled to my personal thoughts. I think we are at the beginning of a yield curve line here on a hockey stick and I believe that 2023 is going to be the year for Rennova Health. Everybody should do their own due diligence but myself, at triple zero one, I don’t think you can get hurt too badly here. Seamus, I am going to give you the last word. What is that you want my listeners and your shareholders to take away from this interview?

Lagan: I think you described us pretty well. I think we have demonstrated what we’ve been promising. We’ve got a recovery well underway and hopefully we can continue to deliver.

Jolly: I want to thank you for coming on the show. Hopefully, you will come back in 30 to40 days and give us an update.

Lagan: Thanks, Everett.

GRAPHIC 4 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 5 rnva-20230222.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 rnva-20230222_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 7 rnva-20230222_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 22, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 22, 2023
Entity File Number	001-35141
Entity Registrant Name	Rennova Health, Inc.
Entity Central Index Key	0000931059
Entity Tax Identification Number	68-0370244
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	400 S. Australian Avenue
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33401
City Area Code	(561)
Local Phone Number	855-1626
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

XML 9 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000931059 2023-02-22 2023-02-22 iso4217:USD shares iso4217:USD shares 0000931059 false 8-K 2023-02-22 Rennova Health, Inc. DE 001-35141 68-0370244 400 S. Australian Avenue Suite 800 West Palm Beach FL 33401 (561) 855-1626 false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://rennovahealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ex99-2.htm rnva-20230222.xsd rnva-20230222_lab.xml rnva-20230222_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "rnva-20230222_lab.xml" ] }, "presentationLink": { "local": [ "rnva-20230222_pre.xml" ] }, "schema": { "local": [ "rnva-20230222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "RNVA", "nsuri": "http://rennovahealth.com/20230222", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-22to2023-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://rennovahealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-02-22to2023-02-22", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://rennovahealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001493152-23-005880-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-005880-xbrl.zip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end